Finance
Chytra Lekarna has been growing its sales by a year on average in the last 5 years.
EBITDA has
grown
by 0%
during that time to total of
CZK 8.14 mil in 2021,
or 2.21% of sales.
That’s compared to 3.26% average margin seen in last five years.
The company netted CZK 3.81 mil in 2021
implying ROE of 18.4% and ROCE of 30.8%.
Again, the average figures were 27.7% and 28.3%, respectively when looking at the previous 5 years.
Chytra Lekarna’s net debt amounted to CZK -7.64 mil at the end of 2021,
or -33.7% of equity.
When compared to EBITDA, net debt was -0.938x,
down when compared to average of -0.238x seen in the last 5 years.
Helgi Library 
